EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular alterations in IDH -mutant astrocytoma: A multi-institutional retrospective study

Keng Lam iD, Hanim I Ozkizilkaya, Denái R Milton, Antonio Dono iD, Yajie Liu, Suprateek Kundu, Vinodh A Kumar, Jason M Johnson, Yoshua Esquenazi iD, Chirag B Patel iD, Leomar Y Ballester iD

Neuro-Oncology Advances · 06.01.2025 · 7 (1)

DOI: 10.1093/noajnl/vdaf088 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 28.04.2025. Verfasst von Keng Lam und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Several molecular alterations have been identified to provide prognosis for patients with isocitrate dehydrogenase (IDH)-mutant astrocytoma. However, contemporary baseline survival data with respect to their molecular alterations are lacking. The prognostic value of histologic grading remains controversial.

Methods

This was a retrospective multi-site study of adult IDH-mutant diffuse astrocytoma patients. Overall survival (OS) was estimated using the Kaplan-Meier method. Associations between OS and measures of interest were evaluated using Cox proportional hazards regression models.

Results

We identified 241 eligible patients. The most frequent mutations were IDH1 (98%), TP53 (91%), ATRX (70%), ARID1A (8%), BRCA2 (6%), TSC2 (6%), CDKN2A (6%), and CREBBP (6%). IDH2 mutations were identified in 2%. By univariate analysis, age > 40 (hazard ratio [HR], 2.03; 95% CI, 1.20-3.45; p = .009) was associated with worse OS. Wildtype BRCA2 compared with mutated BRCA2 (HR, 0.42; 95% CI, 0.20-0.90; p = .024) and Central Nervous System World Health Organization (CNS WHO) grade 2 astrocytoma compared with grade 3 disease (HR, 0.40; 95% CI, 0.21-0.78; p = .007) were associated with better OS. In multivariable analysis, age > 40 (HR, 2.06; 95% CI, 1.18-3.59; p = .011) was associated with worse OS and CNS WHO grade 2 (HR, 0.42; 95% CI, 0.21-0.83; p = .012) remained associated with improved OS. We identified an association between increased tumor mutation burden (TMB) and worse OS.

Conclusions

Age and CNS WHO grade remain essentials for risk stratification among IDH-mutant astrocytoma patients. Further studies are warranted to determine the prognostic implications of BRCA2 mutations and TMB.

Schlagwörter

Stichwörter der Autor:innen

IDH1IDH2WHO gradeastrocytomabrain tumordiffuse gliomamolecular alterationsprognosis

Autor:innen und Institutionen

  • Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Pathology, University of Southern California.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Texas, USA.
  • Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, Texas, USA.
  • Department of Neuroradiology, The University of Texas MD Anderson Cancer, Houston, USA.
  • Radiology and Biomedical Imaging, Yale University, New Haven, USA.

ORCID-Profile: Keng Lam, Antonio Dono, Yoshua Esquenazi, Chirag B Patel, Leomar Y Ballester

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • National Institutes of Health

Zitieren

APA

Lam, K., Ozkizilkaya, H. I., Milton, D. R., Dono, A., Liu, Y., Kundu, S., Kumar, V. A., Johnson, J. M., Esquenazi, Y., Patel, C. B., & Ballester, L. Y. (2025). Molecular alterations in IDH -mutant astrocytoma: A multi-institutional retrospective study. Neuro-Oncology Advances, 7(1). https://doi.org/10.1093/noajnl/vdaf088

Vancouver

Lam K, Ozkizilkaya HI, Milton DR, Dono A, Liu Y, Kundu S, et al. Molecular alterations in IDH -mutant astrocytoma: A multi-institutional retrospective study. Neuro-Oncology Advances. 2025;7(1). doi:10.1093/noajnl/vdaf088

BibTeX
@article{Lam2025,
  author = {Lam, Keng and Ozkizilkaya, Hanim I and Milton, Denái R and Dono, Antonio and Liu, Yajie and Kundu, Suprateek and Kumar, Vinodh A and Johnson, Jason M and Esquenazi, Yoshua and Patel, Chirag B and Ballester, Leomar Y},
  title = {Molecular alterations in IDH -mutant astrocytoma: A multi-institutional retrospective study},
  journal = {Neuro-Oncology Advances},
  year = {2025},
  volume = {7},
  number = {1},
  doi = {10.1093/noajnl/vdaf088}
}
Kostenlos starten →